Popular Searches
Cell Counting Kit-8 (CCK-8)Approved Drug LibraryMG-132Ferrostatin-1Z-VAD-FMK
TargetMol | Star Product
Wikimole
TargetMol | New Product
New Product
TargetMol | Compound Library
Compound Library
Contact Us
Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty
TOPRelated productsBioactivityChemical infoStorage&SolubilityCalculator

SIRT5 inhibitor 7

🥰Excellent
Catalog No. T78803Cas No. 2951090-00-7

SIRT5 inhibitor 7 (compound 58), a substrate-competitive and selective SIRT5 inhibitor with IC 50 = 310 nM, significantly attenuated renal dysfunction and pathological damage in lipopolysaccharide (LPS)- and cecum ligation/perforation (CLP)-induced septic AKI mice, and modulated proteinsuccinimidylation and proinflammatory cytokine release and pro-inflammatory cytokine release in the kidneys of acute kidney injury (AKI) mice.

SIRT5 inhibitor 7

SIRT5 inhibitor 7

🥰Excellent
Purity: 99.77%
Catalog No. T78803Cas No. 2951090-00-7
SIRT5 inhibitor 7 (compound 58), a substrate-competitive and selective SIRT5 inhibitor with IC 50 = 310 nM, significantly attenuated renal dysfunction and pathological damage in lipopolysaccharide (LPS)- and cecum ligation/perforation (CLP)-induced septic AKI mice, and modulated proteinsuccinimidylation and proinflammatory cytokine release and pro-inflammatory cytokine release in the kidneys of acute kidney injury (AKI) mice.
Pack SizePriceAvailabilityQuantity
25 mg$1,670 In Stock
Bulk & Custom
Add to Cart
Questions
View More
Select Batch
Purity:99.77%
Contact us for more batch information
Resource Download
COA HNMR LCMS
With extensive experience in compound synthesis, we can provide rapid custom synthesis services for this product according to your research needs.

Product Introduction

Bioactivity
Description
SIRT5 inhibitor 7 (compound 58), a substrate-competitive and selective SIRT5 inhibitor with IC 50 = 310 nM, significantly attenuated renal dysfunction and pathological damage in lipopolysaccharide (LPS)- and cecum ligation/perforation (CLP)-induced septic AKI mice, and modulated proteinsuccinimidylation and proinflammatory cytokine release and pro-inflammatory cytokine release in the kidneys of acute kidney injury (AKI) mice.
Targets&IC50
SIRT5:310 nM
In vitro
SIRT5 inhibitor 7 is a potent SIRT5 inhibitor with an IC₅₀ of 310 nM, acting as a substrate-competitive and selective inhibitor. In vitro, SIRT5 inhibitor 7 effectively inhibits SIRT5 enzymatic activity and modulates protein succinylation[1].
In vivo
SIRT5 inhibitor 7 was tested in septic AKI mouse models induced by LPS and cecal ligation/perforation (CLP). SIRT5 inhibitor 7 significantly alleviated kidney dysfunction and histopathological injury, and reduced the release of proinflammatory cytokines in kidney tissue[1].
Chemical Properties
Molecular Weight582.12
FormulaC28H32ClN7O3S
Cas No.2951090-00-7
SmilesN(CCCNC(NCCC(O)=O)=S)C=1C(C(=O)N2C[C@H](CC2)C3=CC=CC=C3)=CN=C(NC4=C(Cl)C=CC=C4)N1
Storage & Solubility Information
Storagestore at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice./Shipping at ambient temperature.

Sci Citations

Calculator

  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
TargetMol | Animal experimentsFor example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . TargetMol | Animal experiments A total of 10 animals were administered, and the formula you used is 5% TargetMol | reagent DMSO+30% PEG300+5% Tween 80+60% Saline/PBS/ddH2O. So your working solution concentration is 2 mg/mL。
Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSOTargetMol | reagent (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
Preparation method for in vivo formula: Take 50 μL DMSOTargetMol | reagent main solution, add 300 μLPEG300TargetMol | reagent mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLSaline/PBS/ddH2OTargetMol | reagent mix well and clarify
For Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
1 Enter information below:
mg/kg
g
μL
2 Enter the in vivo formulation:
% DMSO
%
% Tween 80
% Saline/PBS/ddH2O

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Related Tags: buy SIRT5 inhibitor 7 | purchase SIRT5 inhibitor 7 | SIRT5 inhibitor 7 cost | order SIRT5 inhibitor 7 | SIRT5 inhibitor 7 chemical structure | SIRT5 inhibitor 7 in vivo | SIRT5 inhibitor 7 in vitro | SIRT5 inhibitor 7 formula | SIRT5 inhibitor 7 molecular weight
TargetMol | Logo

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.